CBD and postpartum depression and baby blues: what science says about safety

The first weeks after childbirth involve a dramatic hormonal change combined with sleep deprivation and new responsibilities. According to the World Health Organization, about 13% of women who have just given birth experience a mental disorder, most often depression. At the same time, the number of social media posts recommending CBD oil as a natural support is increasing. This article asks questions in a different order than those recommendations: first about the safety of the child, then about the effectiveness for the mother. The answer to the first question is today unequivocal and comes from the position of the European Food Safety Authority, while the answer to the second is much weaker than the headlines suggest. Along the way, we clarify some numbers that circulated in the previous version of this text in a distorted form regarding the work they referred to.

KEY INFORMATION
• WHO: about 13% of women after childbirth experience a mental disorder, most often depression; in developing countries, 19.8%.
• EFSA 2026: the safety of CBD cannot be established in breastfeeding women, individuals under 25 years of age, and those taking medications.
• In the milk of 50 women using marijuana, THC was detected in 63% of samples, cannabidiol only in 5 out of 54 (Bertrand et al., Pediatrics 2018).
• Postpartum depression is a condition treated with psychotherapy or pharmacotherapy, not a supplement.

What is baby blues and what is postpartum depression?

The distinction determines what needs to be done. Baby blues is a temporary mood swing in the first days after childbirth, characterized by tearfulness, irritability, and anxiety, usually resolving before the end of the second week. It does not require treatment, but rather rest and support from the environment.

Postpartum depression is a clinical condition: a persistent low mood lasting more than two weeks with a loss of joy in motherhood, sleep disturbances unrelated to the child’s needs, intrusive thoughts, and difficulty in caregiving and bonding. It does not resolve on its own and requires intervention.

The scale is large and well documented. The World Health Organization states that about 10% of pregnant women and about 13% of women who have just given birth experience a mental disorder, primarily depression, with rates in developing countries being 15.6% and 19.8% respectively (WHO, maternal mental health). The previous version of this article cited a range of 10-15% and referred to a link that now returns a 404 error, as well as attributing 50-80% of mothers to baby blues without indicating a source. The number without a source has been removed from the text.

Delaying help in the hope that “it will pass on its own” or that “a supplement will be enough” delays treatment and deepens the illness. This is the most important sentence of this article and stands here before any discussion about cannabinoids.

What does science say about CBD and breastfeeding?

The most frequently cited measurement concerns women using marijuana, not women using cannabidiol products, and this distinction changes the meaning of the result. It is worth reading it carefully, as it circulates in a distorted version.

In the work of Bertrand et al. (Pediatrics, 2018), fifty breastfeeding women reporting marijuana use provided a total of 54 milk samples between 2014 and 2017. THC was detected in 34 samples, or 63%, up to about six days after the last reported use, with a median concentration of 9.47 ng/ml. Cannabidiol or 11-hydroxy-THC appeared in only five samples, with concentrations of cannabidiol ranging from 1.32 to 8.56 ng/ml. Cannabinol was not found in any sample.

The previous version of this article distorted this result in three ways at once. It stated that cannabidiol persists for six days, while six days refers to THC. It mentioned fifty women in the text, but twenty-five in the structured data. It also added that THC persists “up to six weeks,” which is not present in this work. The identifier under which all this was listed led to an article about organometallic materials.

The proper basis for caution lies elsewhere. The update of the position of the European Food Safety Authority (EFSA, NDA panel, 2026) states directly that the safety of cannabidiol cannot be established for breastfeeding women, for individuals under 25 years of age, and for those taking medications. This last group includes a significant portion of postpartum women.

Why does infant exposure to cannabinoids raise concerns?

The reason is the role of the endocannabinoid system in brain development, not measured harm to a specific child. Endocannabinoids participate in the proliferation of neurons, their migration, synapse formation, and myelination, which are processes that occur most intensively in the first months of life.

A cannabinoid delivered from outside may interfere with this signaling. Whether the interference is neutral, beneficial, or harmful is unknown, as no one has measured this in infants. The EFSA position notes that after prenatal exposure in animal models, long-lasting and sex-dependent neurodevelopmental effects were observed, and no study has yet investigated the immunotoxicity of cannabidiol.

The clinical report of the American Academy of Pediatrics (Ryan et al., Pediatrics 2018) indicates the ability of cannabinoids to cross the placenta as a reason for concerns about both the course of pregnancy and distant consequences for the child, and separately refers to breastfeeding. This is a document about cannabis as a substance, not about cannabidiol itself, and should be read as such.

It is worth mentioning something that is easily overlooked: the lack of data is not evidence of harm. It is, however, a reason not to take risks when there is treatment with a described safety profile. Such treatment exists for postpartum depression.

What really works for postpartum depression?

Postpartum depression is a treatable and well-researched condition, and the methods with the strongest evidence are psychological and pharmacological. None of them is a supplement.

Cognitive-behavioral therapy and interpersonal therapy are among the best-researched methods for mild to moderate postpartum depression, and they do not carry the side effects associated with medications. In Poland, access is through a referral within public services or through a private practice.

Pharmacotherapy is an option that breastfeeding does not exclude. The choice of medication, assessment of its compatibility with lactation, and supervision of treatment are the responsibility of a psychiatrist, preferably with perinatal experience. Abandoning treatment for depression “for the child’s sake” is a decision that usually harms both, as untreated maternal depression affects caregiving and bonding.

The third pillar is support in daily life: the presence of loved ones, division of responsibilities allowing the mother to sleep, and contact with other women at the same life stage. A previously listed list of foundations and organizations that we could not confirm as providing support for mothers with postpartum depression in Poland has been removed. Current addresses are known by the community midwife and family doctor, and this is the easiest place to start.

Is there a situation in which CBD can be considered after childbirth?

Yes, but it is narrow and clearly defined. A woman who has finished breastfeeding no longer exposes her child through milk, so the main source of uncertainty disappears. Questions about her own well-being remain.

Even then, cannabidiol is not a treatment for postpartum depression, either first-line or second-line. It is at most an adjunct after breastfeeding has ended, in cases of mild symptoms and under medical supervision, alongside psychotherapy, not instead of it. EFSA excludes from safety assessment individuals taking medications, so in the case of concurrent antidepressant treatment, a conversation with a doctor precedes everything else. A broader compilation of data on pregnancy and lactation has been gathered in the text CBD and pregnancy and breastfeeding.

When thoughts of self-harm or harming the child arise, there is no room for considerations about supplements. The emergency number is 112. Support in a mental health crisis is provided by the Crisis Trust Line at 116 123, operated by the Institute of Health Psychology and intended for adults in emotional crisis. The previous version of this article described this number as a hotline for women, which does not correspond to its purpose.

There is one more situation worth stating directly. Some women turn to cannabidiol not because they believe in its effectiveness, but because it is easier to buy oil than to schedule an appointment with a psychiatrist, and the supplement does not carry the label of a mental illness. This instinct is understandable and can signal: if you are thinking about CBD for postpartum symptoms, it means you need support. The support worth seeking has research backing, which cannabidiol does not have in this indication.

What does neurobiology say about CBD and mood?

Interest in cannabidiol in depression has biological foundations, but it does not translate into clinical evidence in this specific population. The endocannabinoid system participates in mood regulation, stress reactivity, and neuroplasticity, and postpartum depression is associated, among other things, with dysregulation of the hypothalamic-pituitary-adrenal axis.

The most frequently cited clinical study is Shannon et al. (The Permanente Journal, 2019). This is a retrospective review of psychiatric clinic records, ultimately involving 72 adult patients presenting with anxiety or poor sleep quality. Anxiety scores decreased in the first month in 57 individuals, or 79.2%, and remained at a lower level. Sleep scores improved in 48 individuals, or 66.7%, but fluctuated over time. The authors conclude that controlled studies are needed.

Three caveats must be placed alongside these numbers. The review of records does not have a control group, so it does not account for the placebo effect or natural course. The participants were not postpartum women. Cannabidiol was administered as an adjunct to existing treatment, not instead of it. The identifier that was previously here actually led to a completely different work, a review of cannabidiol in anxiety disorders from 2020.

Biological justification is therefore not a recommendation. More on the depressive thread is discussed in the texts CBD and the treatment of depression and Depression and cannabis.

What risk factors for postpartum depression can be detected earlier?

Postpartum depression rarely comes without warning, and some factors can be recognized even during pregnancy. Knowledge of them can be more practical than searching for a supplement, as it leads to specific actions before symptoms appear.

The strongest single factor is a previous episode of depression or anxiety disorder. Other factors include weak support from a partner and family, difficult living conditions, perinatal complications, and chronic sleep deprivation due to colic or feeding problems. A separate factor is the lack of a plan for who will realistically help in the first weeks. We have removed the previously provided multiple of risk from this place, as it did not have a specified source.

A woman with a history of depression should be under careful observation and have a plan established before childbirth, rather than waiting for symptoms. It is worth starting this conversation with the person conducting the pregnancy, as they will direct further and know the available pathways in the area.

A pre-birth plan does not have to be complicated. It is enough to establish who will take over night feedings once or twice a week so that the mother can sleep for a longer stretch, and who will call for help if symptoms appear. A pre-arranged contact with a psychologist or psychiatrist saves weeks of searching at a time when there is no strength left to search. This intervention has no clinical trials and no cost, and it takes away two of postpartum depression’s strongest allies: insomnia and isolation.

How to talk to a doctor about CBD after childbirth?

Openly and without beating around the bush, as silence is the only real risk here. A doctor who does not know what the patient is taking cannot assess interactions or plan treatment.

Fear of judgment is understandable and common. However, it is worth remembering that asking about supplements is part of routine history-taking, and information about cannabidiol is for the doctor an indication of a substance affecting the metabolism of other medications, not a moral judgment. EFSA notes that the hepatotoxic potential of cannabidiol in humans primarily reveals itself when used concurrently with medications, making this conversation practically necessary.

Three questions are worth preparing in advance. Is cannabidiol safe with my current treatment? Can I return to it after breastfeeding? What are my options if I want to start with therapy rather than medication? Answers to each of these depend on the specific situation, which is why they are not included in any article, including this one.

It can also be helpful to bring the product packaging to the appointment. Labels differ in the declared content of cannabidiol, form, and carrier composition, and for assessing interactions, this is more significant than the brand name. If the product does not have a certificate of analysis, the doctor has nothing to evaluate, and this is also an answer to the question of safety. The conversation lasts a few minutes and usually ends with one of two recommendations: stop during treatment or return to the topic after breastfeeding ends.

Frequently asked questions

Is CBD safe after childbirth?

When breastfeeding, safety cannot be established, and this is the conclusion of the EFSA from 2026, covering breastfeeding women, individuals under 25 years of age, and those taking medications. ACOG and the American Academy of Pediatrics advise against the use of marijuana during lactation due to a lack of data on infant exposure.

Does CBD pass into breast milk?

In a study of the milk of fifty women using marijuana, cannabidiol was detected in five out of 54 samples, with concentrations ranging from 1.32 to 8.56 ng/ml (Bertrand et al., Pediatrics 2018). The six-day persistence referred to THC, not cannabidiol. CBD products were not included in this study.

How to treat postpartum depression without CBD?

Cognitive-behavioral or interpersonal psychotherapy, pharmacotherapy tailored by a psychiatrist, and support in daily care. Breastfeeding does not exclude pharmacological treatment, and the choice of medication compatible with lactation is up to the doctor. In mild cases, psychotherapy may be the first-line treatment.

Can CBD harm an infant?

There are no studies measuring this, which is why caution is advised. EFSA notes neurodevelopmental effects after prenatal exposure in animal models, long-lasting and sex-dependent, and there are no studies on the immunotoxicity of cannabidiol.

What is baby blues and how to distinguish it from postpartum depression?

Baby blues is a temporary mood swing in the first days after childbirth, usually resolving within two weeks and not requiring treatment. Postpartum depression lasts longer, involves loss of joy and difficulty in caring for the child, and requires psychological or psychiatric intervention.

Did studies on CBD and anxiety involve women after childbirth?

No. The most frequently cited study by Shannon et al. 2019 is a retrospective review of the records of 72 adult patients from a psychiatric clinic, without a control group. Anxiety scores improved in 79.2% of them, but the authors themselves indicate the need for controlled studies.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-28 · Updated: 2026-08-15